Methods for Studying Myofibroblast Apoptotic Pathways

Area of Science:

• Cell Biology
• Biochemistry
• Pathology

Background:

• Myofibroblast apoptosis evasion drives fibrotic diseases by promoting extracellular matrix deposition.
• Targeting myofibroblast apoptosis is a promising therapeutic strategy for reversing fibrosis.
• Fibroblast-to-myofibroblast transdifferentiation increases mitochondrial priming for apoptosis.

Purpose of the Study:

• To introduce BH3 profiling as a method to measure myofibroblast apoptotic priming.
• To assess myofibroblast dependencies on pro-survival BCL-2 proteins.
• To predict myofibroblast response to BH3 mimetic drugs and evaluate extrinsic apoptosis sensitivity.

Main Methods:

• BH3 profiling to quantify apoptotic priming and anti-apoptotic dependencies in myofibroblasts.
• Assessment of myofibroblast sensitivity to extrinsic apoptosis using Annexin V staining.
• Utilizing BH3 profiling to predict responses to targeted pro-survival BCL-2 protein therapies.

Main Results:

• Stiffness-activated myofibroblasts exhibit significantly increased "mitochondrial priming," indicating a "primed for death" state.
• This apoptosis-prone phenotype is driven by high pro-apoptotic proteins, counteracted by pro-survival BCL-2 proteins.
• BH3 profiling effectively measures this priming and predicts drug responses.

Conclusions:

• Myofibroblasts are not inherently apoptosis-resistant but can be poised for death when survival pathways are blocked.
• BH3 profiling is a valuable tool for understanding myofibroblast apoptosis regulation and guiding therapeutic strategies.
• This approach can predict patient response to BH3 mimetic drugs, advancing fibrosis treatment.